No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

11/4

Novo Nordisk

Ascendis Pharma

GLP-1 Receptor Agonist,

TransCon technology platform

GLP-1R

Obesity, type 2 diabetes,

Discovery

362.5

2

11/8

Daiichi Sankyo

Alteogen

Hybrozyme Technology ALT-B4

ENHERTU SC route

-

Discovery

280

3

11/12

Apollo

Therapeutics

Sunshine Lake

Pharma

Bi-specific fusion protein
(HEC-88473)

FGF21 / GLP-1 Dual Receptor Agonist

MASH, type 2 diabetes,

 obesity

Phase II

938

4

11/14

Merck

LaNova Medicines

Bispecific antibody

(LM-299)

PD-1 and VEGF

Solid tumor

Phase II

3,288

5

11/18

Novartis

Ratio Therapeutics

Radiopharmaceutical

comprises of radioisotope

actinium-225

Somatostatin Receptor

Type 2 (SSTR2)

Unspecified cancer

Discovery

745

6

11/20

Kura Oncology

Kyowa Kirin

Small molecule

(ziftomenib)

Menin

Type 2 Diabetes, ALL, AML,

GIST, solid tumor

Phase II

1,491

7

11/26

Sarepta

Therapeutics

Arrowhead

Pharmaceuticals

siRNA

 (ARODUX-4

/AROMMP-7

/ARO-DM1)

Double Homeobox Protein 4

/Matrilysin

/Myotonin Protein Kinase

Facioscapulohumeral

muscular dystrophy

/IPF

/DM1

Phase II

1,075

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

11/13

BioNTech

Biotheus

PM-8002

Type : Bi-specific monoclonal antibody

Target : PDL1 and VEGF A

Indication : Solid tumors

Stage : Phase 3

950

2

11/21

Novartis

Kate Therapeutics

DELIVER capsid engineering and

cargo platform

Type : Gene Therapy, adeno-associated virus (AAV)

Target : double homeobox protein 4 (DUX4)

Indication : myotonic dystrophy type 1 (DM1),

 facioscapulohumeral dystrophy (FSHD),

 genetic muscular dystrophy, genetic cardiomyopathy

Stage : Discovery

1,100

3

11/26

Roche

Poseida Therapeutics

P-MUC1C-ALLO1

Type : Allogeneic CAR-T

Target : Mucin 1

Indication : Solid tumors, autoimmune disease

Stage : Phase 1

1,500